Prescribing Information & Guidance

Resources For Health Professionals


Rybelsus® (oral Semaglutide) Tablets


This guidance includes information relating to the switching from injectable GLP1 Receptor agonists to oral semaglutide

Approved by the BLMK APC Feb 2023

View Document

Guideline Categories: Endocrinology and Diabetes

Guideline Areas: Bedfordshire, Luton, Milton Keynes

Guideline Tags: GLP1 receptor agonists, GLP1-RAs, semaglutide, switching

Please use the search box to search the whole site if you can't find what you're looking for:

To top
Welcome to the BLMK Medicines Optimisation website.
This site is currently being updated.

If you have any feedback or find any issues, please email the team:
BLMKICB.MedsOpt@nhs.net